abbv-927
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 28, 2017 (NCT02988960)
Timeline
Indications
Mechanism of action
- Tumor necrosis factor receptor superfamily member 5Immunity, passive
CD40 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- abbv-927
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04807972 | Phase 2 | May 28, 2021 | AbbVie |
| NCT03893955 | Phase 1 | May 21, 2019 | AbbVie |
| NCT03818542 | Phase 1 | Mar 8, 2019 | AbbVie |
| NCT02988960 | Phase 1 | Feb 28, 2017 | AbbVie |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 4 | 4 | 2 | 2017 |
1 organizations
Page 1 / 1